Drug Trial Radar · NCT01529268
Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children
Last checked: Nov 19, 2026Latest source record: Jun 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
169
Actual
Start
Jun 2012
Primary completion
Mar 2015
Study completion Sep 2015
Sponsor
- Sponsor type
- NIH
- Collaborators
- National Center for Advancing Translational Sciences (NCATS); National Cancer Institute (NCI); Raptor Pharmaceuticals
- First posted
- Feb 8, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 8 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CyNCh is a multi-center, placebo-controlled clinical trial of children ages 8 to 17 years with biopsy-confirmed moderate to severe nonalcoholic fatty liver disease (NAFLD). The primary objective is to evaluate whether 52 weeks of treatment with cysteamine bitartrate delayed-release capsules will result in improvement in liver disease severity.
Conditions
- Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions
DR cysteamine bitartrate capsuleDrug
* 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline * 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline * 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline
DR cysteamine bitartrate placeboOther
* 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline * 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline * 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement in Nonalcoholic Fatty Liver Disease (NAFLD)Time frame: 52 weeks
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
University of California, San Diego
San Diego, California
University of California, San Francisco
San Francisco, California
Emory University
Atlanta, Georgia
Ann & Robert H. Lurie Children's Hospital of Chicago (NWU)
Chicago, Illinois
Indiana University
Indianapolis, Indiana
St. Louis University
St Louis, Missouri
Columbia University
New York, New York
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Texas Children's Hospital
Houston, Texas
University of Washington, Seattle Children's Hospital
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.